Incyte Corp. (INCY)
123.22
-1.15
(-0.92%)
USD |
NASDAQ |
Aug 31, 16:00
123.19
-0.03
(-0.02%)
After-Hours: 20:00
Incyte Cash from Operations (TTM) : 1.980B for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.980B |
| March 31, 2026 | 1.517B |
| December 31, 2025 | 1.413B |
| September 30, 2025 | 1.251B |
| June 30, 2025 | 1.003B |
| March 31, 2025 | 382.59M |
| December 31, 2024 | 335.34M |
| September 30, 2024 | 101.85M |
| June 30, 2024 | -61.19M |
| March 31, 2024 | 820.90M |
| December 31, 2023 | 496.49M |
| September 30, 2023 | 632.42M |
| June 30, 2023 | 780.97M |
| March 31, 2023 | 648.60M |
| December 31, 2022 | 969.94M |
| September 30, 2022 | 801.63M |
| June 30, 2022 | 760.35M |
| March 31, 2022 | 759.13M |
| December 31, 2021 | 749.49M |
| September 30, 2021 | 741.46M |
| June 30, 2021 | 668.48M |
| March 31, 2021 | 764.91M |
| December 31, 2020 | -124.60M |
| September 30, 2020 | -100.30M |
| June 30, 2020 | -12.00M |
| Date | Value |
|---|---|
| March 31, 2020 | -128.42M |
| December 31, 2019 | 710.66M |
| September 30, 2019 | 662.88M |
| June 30, 2019 | 591.61M |
| March 31, 2019 | 471.05M |
| December 31, 2018 | 336.23M |
| September 30, 2018 | 172.06M |
| June 30, 2018 | 26.03M |
| March 31, 2018 | 109.58M |
| December 31, 2017 | -92.99M |
| September 30, 2017 | 81.72M |
| June 30, 2017 | 123.87M |
| March 31, 2017 | 25.49M |
| December 31, 2016 | 304.76M |
| September 30, 2016 | 280.39M |
| June 30, 2016 | 192.84M |
| March 31, 2016 | 188.66M |
| December 31, 2015 | 86.54M |
| September 30, 2015 | 61.62M |
| June 30, 2015 | 81.31M |
| March 31, 2015 | 53.36M |
| December 31, 2014 | 25.99M |
| September 30, 2014 | -19.53M |
| June 30, 2014 | -60.38M |
| March 31, 2014 | -47.52M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Mirum Pharmaceuticals, Inc. | -227.27M |
| Regeneron Pharmaceuticals, Inc. | 4.681B |
| Eli Lilly & Co. | 28.08B |
| AbbVie, Inc. | 19.51B |
| Biogen, Inc. | 2.879B |